Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma
NCT: NCT01892397 · ACTIVE_NOT_RECRUITING
Brief Summary
The purpose of this study is to find out what effects, good or bad, the Optune device has on the patient and meningioma. This study is being done because currently there are no proven effective medical treatments for a progressive meningioma that has failed surgery and/or radiation. The study uses an experimental device called Optune. Optune is "experimental" because it has not been approved by the U.S. Food and Drug Administration (FDA) for this type of tumor, although it has been approved for a different type of brain tumor.
Frequently Asked Questions
What is Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma?
Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma is a clinical trial registered under NCT01892397. Current status: ACTIVE_NOT_RECRUITING.
What is the status of NCT01892397?
The current status of NCT01892397 (Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma) is: ACTIVE_NOT_RECRUITING.
When did Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma start?
Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma started on 2013-06.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.